Journal article
Filgotinib for the treatment of rheumatoid arthritis
- Abstract:
-
Introduction: Biologics were the first targeted therapies for rheumatoid arthritis (RA), having in common high clinical efficacy. Being proteins, they are administered parenterally. The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme family which mediate signalling for a cytokine subset important in RA pathogenesis. Areas covered: Several JAK inhibitors have been developed with differing selectivity for the four JAK enzymes with...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted manuscript
Actions
Access Document
- Files:
-
-
(pdf, 177.9KB)
-
(pdf, 18.9KB)
-
(jpeg, 32.3KB)
-
(pdf, 16.1KB)
-
- Publisher copy:
- 10.1080/13543784.2017.1372422
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Bibliographic Details
- Publisher:
- Taylor and Francis Publisher's website
- Journal:
- Expert Opinion on Investigational Drugs Journal website
- Volume:
- 26
- Issue:
- 10
- Pages:
- 1181-1187
- Publication date:
- 2017-08-24
- Acceptance date:
- 2017-08-24
- DOI:
- EISSN:
-
1744-7658
- ISSN:
-
1354-3784
- Pubs id:
-
pubs:725767
- URN:
-
uri:3e4afb6e-5cb2-4c28-840d-154bb0bf7cbc
- UUID:
-
uuid:3e4afb6e-5cb2-4c28-840d-154bb0bf7cbc
- Local pid:
- pubs:725767
Terms of use
- Copyright date:
- 2017
- Notes:
- This is the author accepted manuscript following peer review version of the article. The final version is available online from Taylor and Francis at: 10.1080/13543784.2017.1372422
If you are the owner of this record, you can report an update to it here: Report update to this record